Latest Headlines

Latest Headlines

ImmunoGen plummets as its Roche-partnered cancer drug comes up short

ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair's targeted cancer drug, casting doubts on the biotech's technology for creating armed antibodies.

ImmunoGen scuttles lead PhII armed-antibody trial after tracking infection risk

ImmunoGen garnered considerable attention for the tech support role it played on Roche's armed antibody Kadcyla. But an attempt to steer one of its own antibody-drug conjugates through clinical studies ended in disaster today.

ImmunoGen bags ADC deal with Novartis

Antibody-drug conjugate superstar ImmunoGen has signed another agreement to lend its targeted drug technology to Novartis for an undisclosed cancer therapy.

Eli Lilly inks $200M armed antibody pact with ImmunoGen

ImmunoGen says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies.

Genentech nabs FDA approval for T-DM1 cancer killer

Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Roche, ImmunoGen gain speedy review for T-DM1 breast cancer breakthrough

Roche has gained the inside track in the final lap of a long and expensive race to win an FDA approval for the armed antibody T-DM1, a new approach to treating HER2-positive breast cancer that marks a significant advance for patients.

Roche, ImmunoGen's T-DM1 boosts cancer survival

Roche and ImmunoGen's trastuzumab emtansine (T-DM1) slashed the risk of death by almost a third compared with standard treatment in the EMILIA Phase III trial in women with advanced breast cancer.

UPDATED: T-DM1 survival rate wows as Roche pushes for megablockbuster approval

Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.

ImmunoGen celebrates T-DM1 Phase III success with market plans

ImmunoGen's ($IMGN) antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM1) has significantly improved survival in a Phase III trial in women with advanced breast cancer, and the agent has been submitted for marketing approval.